Prognostic factors in Buprenorphine- versus methadone-maintained patients

Area of Science:

• Addiction Medicine
• Psychiatry
• Pharmacology

Background:

• Opioid use disorder (OUD) treatment often involves medication-assisted treatment.
• Buprenorphine and methadone are common medications for OUD, with differing pharmacological profiles.
• Understanding factors influencing treatment outcomes, such as gender and co-occurring psychopathology, is crucial.

Purpose of the Study:

• To compare buprenorphine and methadone maintenance effects on benzodiazepine and alcohol use.
• To evaluate the prognostic significance of gender and psychopathology in OUD treatment.
• To examine the interaction between patient characteristics and maintenance medication type.

Main Methods:

• Randomized controlled trial comparing buprenorphine and methadone.
• Inclusion of 80 male and 36 female patients with OUD.
• Variable dosing of buprenorphine (4 or 12 mg) and methadone (20 or 65 mg).
• Assessment of benzodiazepine, alcohol, and illicit opioid use, retention rates, and urine toxicology.

Main Results:

• No significant differences in benzodiazepine or alcohol use between buprenorphine and methadone groups.
• Females showed higher abstinence rates from illicit opioids, particularly in the 4 mg buprenorphine group.
• The 4 mg buprenorphine group with females demonstrated better retention and lower opioid-positive urine samples.
• Lifetime sedative dependence was linked to better retention and improved cocaine abstinence, especially with buprenorphine.

Conclusions:

• Neither buprenorphine nor methadone showed superiority in reducing benzodiazepine and alcohol use.
• Female gender and buprenorphine treatment (4 mg) were associated with improved outcomes in OUD.
• Sedative dependence history may predict better treatment response in certain contexts, particularly with buprenorphine.